|
...
Novel Adjuvants:
3.1 Adjuvant selection and availability: Because of the limited global capacity to produce sufficient novel influenza A (H1N1) vaccine antigen to immunize the global population and the possibility that a single dose of unadjuvanted vaccine may not yield an adequate immune response, antigen sparing techniques, such as administration of reduced quantities of antigen with the oil-in-water adjuvants ASO3 (manufactured by GSK) and MF-59 (manufactured by Novartis) are being considered. There are currently no U.S. licensed influenza vaccines containing an adjuvant.
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
14 | Agenus - neue WKN - es tut sich was | moneywork4me | schmidin01 | 19.12.24 08:08 | ||
4 | 291 | Neustart mit "frischem Kapital" | Heron | akfan | 17.07.24 19:12 | |
Agenus 4,5 $ | Berndthc | 25.04.21 11:25 | ||||
130 | Ist was durchgesickert?? | Friends | alice.im.börsenland | 16.04.12 15:13 | ||
5 | Antigenics auf Einstiegsniveau? | xpfuture | Friends | 10.06.09 19:52 |